We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

RXII
RXi Pharmaceuticals Corporation
NasdaqCM
People also watch : GALE CYTR OPXA CYCC RNN
2.22 -0.08 (-3.48%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • Max
1d
Prev Close 2.30
Open 2.30
Bid 0.00 x
Ask 3.40 x 100
52wk Range 1.26 - 6.49
Day's Range 2.21 - 2.34
Volume 31,701
Avg Vol (3m) 80,504
As of 4:00 PM EDT. Market closed.
  • Capital Cube 5 hours ago

    ETF’s with exposure to RXi Pharmaceuticals Corp. : July 20, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to RXi Pharmaceuticals Corp.Here are 5 ETF’s with the largest exposure to RXII-US. Comparing the performance and risk of RXi Pharmaceuticals Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us […] (Read more...) The post ETF’s with exposure to RXi Pharmaceuticals Corp. : July 20, 2016 appeared first on CapitalCube.

  • Capital Cube last month

    RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016

    Click here to see latest analysisRXi Pharmaceuticals Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of RXi Pharmaceuticals Corp. – WaferGen Bio-systems, Inc., Neuralstem, Inc., Heron Therapeutics Inc and Histogenics Corp. (WGBS-US, CUR-US, HRTX-US and HSGX-US) that have also reported for this period.HighlightsSummary numbers: […] (Read more...) The post RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.

  • Capital Cube 4 months ago

    RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: 2015 By the Numbers

    Click here to see latest analysisRXi Pharmaceuticals Corp. reports financial results for the year ended December 31, 2015.HighlightsNarrowing of operating margins contributed to decline in earnings.The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:N/A2012201320142015Relevant Numbers (Annual)RevenuesN/A0.10.40.070.03Revenue Growth (YOY)N/AN/AN/AN/AN/AEarningsN/A-12.88-20.93-8.8-10.22Earnings Growth (YOY)N/AN/A-62.4657.95-16.17Net MarginN/A-13278.35-5244.36-12394.37-30067.65EPSN/A-5.7-2.88-0.79-0.21Return on EquityN/A-661.22-352.7-124.83-124.6Return on […] (Read more...) The post RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: 2015 By the Numbers appeared first on CapitalCube.

  • Capital Cube 9 months ago

    RXi Pharmaceuticals Corp.: A look at fundamentals

    Capitalcube gives RXi Pharmaceuticals Corp. a score of 55.Our analysis is based on comparing RXi Pharmaceuticals Corp. with the following peers – WaferGen Bio-systems, Inc., Neuralstem, Inc., Heron Therapeutics Inc and Histogenics Corp. (WGBS-US, CUR-US, HRTX-US and HSGX-US).Investment OutlookRXi Pharmaceuticals Corp. has a fundamental score of 55 and has a relative valuation of NEUTRAL.Access our […] (Read more...) The post RXi Pharmaceuticals Corp.: A look at fundamentals appeared first on CapitalCube.

  • Capital Cube 10 months ago

    RXi Pharmaceuticals Corp. Earnings Q2, 2015

    RXi Pharmaceuticals Corp. reports preliminary financial results for the quarter ended June 30, 2015.RXi Pharmaceuticals Corporation (RXII-US) is one of the first companies amongst its peer group to announce earnings for this period.HighlightsChange in operating cash flow of 10.76% compared to same quarter last year is about the same as change in earnings, likely no […] (Read more...) The post RXi Pharmaceuticals Corp. Earnings Q2, 2015 appeared first on CapitalCube.

  • TheStreet.com last year

    3 Stocks Under $10 to Trade for Breakouts

    These under-$10 stocks are within range of triggering breakout trades.

  • Seeking Alpha 3 years ago

    Rxi Pharmaceuticals, Significant Upside Of 300% Is Expected In Coming Months

    Rxi Pharmaceuticals ( OTCQX:RXII ) is an RNAi biotechnology company that is developing RNAi drug candidates for unmet medical needs. One of its main drugs is known as RXI-109 being developed to treat patients ...